Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $60.75 million. The enterprise value is $166.44 million.
| Market Cap | 60.75M |
| Enterprise Value | 166.44M |
Important Dates
The last earnings date was Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 189.85 million shares outstanding. The number of shares has increased by 20.47% in one year.
| Current Share Class | 189.85M |
| Shares Outstanding | 189.85M |
| Shares Change (YoY) | +20.47% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 48.84% |
| Float | 146.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.40 |
| Forward PS | 0.80 |
| PB Ratio | 10.35 |
| P/TBV Ratio | 10.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 21.48.
| Current Ratio | 2.49 |
| Quick Ratio | 1.44 |
| Debt / Equity | 21.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.76 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.80% |
| Return on Invested Capital (ROIC) | -4.46% |
| Return on Capital Employed (ROCE) | -6.79% |
| Weighted Average Cost of Capital (WACC) | 9.26% |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | -$266,008 |
| Employee Count | 128 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.94% in the last 52 weeks. The beta is 1.66, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | -75.94% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 26.30 |
| Average Volume (20 Days) | 2,685,031 |
Short Selling Information
The latest short interest is 43.24 million, so 22.78% of the outstanding shares have been sold short.
| Short Interest | 43.24M |
| Short Previous Month | 42.63M |
| Short % of Shares Out | 22.78% |
| Short % of Float | 29.51% |
| Short Ratio (days to cover) | 17.36 |
Income Statement
In the last 12 months, HRTX had revenue of $151.18 million and -$34.05 million in losses. Loss per share was -$0.18.
| Revenue | 151.18M |
| Gross Profit | 93.63M |
| Operating Income | -10.86M |
| Pretax Income | -34.05M |
| Net Income | -34.05M |
| EBITDA | -8.73M |
| EBIT | -10.86M |
| Loss Per Share | -$0.18 |
Balance Sheet
The company has $42.66 million in cash and $148.35 million in debt, with a net cash position of -$105.69 million or -$0.56 per share.
| Cash & Cash Equivalents | 42.66M |
| Total Debt | 148.35M |
| Net Cash | -105.69M |
| Net Cash Per Share | -$0.56 |
| Equity (Book Value) | 6.91M |
| Book Value Per Share | 0.03 |
| Working Capital | 137.70M |
Cash Flow
In the last 12 months, operating cash flow was -$11.61 million and capital expenditures -$529,000, giving a free cash flow of -$12.14 million.
| Operating Cash Flow | -11.61M |
| Capital Expenditures | -529,000 |
| Depreciation & Amortization | 2.13M |
| Net Borrowing | -12.76M |
| Free Cash Flow | -12.14M |
| FCF Per Share | -$0.06 |
Margins
Gross margin is 61.93%, with operating and profit margins of -7.19% and -22.52%.
| Gross Margin | 61.93% |
| Operating Margin | -7.19% |
| Pretax Margin | -22.52% |
| Profit Margin | -22.52% |
| EBITDA Margin | -5.78% |
| EBIT Margin | -7.19% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.47% |
| Shareholder Yield | -20.47% |
| Earnings Yield | -56.05% |
| FCF Yield | -19.97% |
Analyst Forecast
The average price target for HRTX is $2.00, which is 525.00% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.00 |
| Price Target Difference | 525.00% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 1.20% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
HRTX has an Altman Z-Score of -9.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.21 |
| Piotroski F-Score | 2 |